Chemistry Reference
In-Depth Information
[428] Omagari K, Mitomo D, Kubota S, Nakamura H, Fukunishi Y. A method to enhance the hit
ratio by a combination of structurebased drug screening and ligand-based screening. Adv.
Appl. Bioinform. Chem., 2008, 1: 19-28.
[429] Villoutreix BO, Renault N, Lagorce D, Sperandio O,Montes M, Miteva MA. Free resources
to assist structure-based virtual ligand screening experiments. Curr. Protein Pept. Sci.,
2007, 8: 381-411.
[430] Leeson PD, St-Gallay SA. The influence of the 'organizational factor' on compound quality
in drug discovery. Nat. Rev. Drug Discov. 2011, 10: 749-765.
[431] Michel J, Essex JW. Prediction of protein-ligand binding affinity by free energy
simulations: assumptions, pitfalls and expectations. J. Comp. Aided Mol Des. 2010, 24:
639-658.
[432] Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov.,
2009, 8: 959-968.
[433] Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth?
Drug Discov. Today, 2005, 10: 1031-1039.
[434] Williams R. Discontinued drugs in 2008: oncology drugs. Exp. Opin. Invest. Drugs, 2009,
18: 1581-1594.
[435] Harrison C. The patent cliff steepens. Nat. Rev. Drug Discov. 2011, 10: 12-13.
[436] LaMattina JL. The impact of mergers on pharmaceutical R&D. Nat. Rev. Drug Discov.,
2011, 10: 559-560.
[437] Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for
industry-academic partnerships. Drug Discov. Today, 2009, 14: 95-101.
[438] Triggle DJ. The chemist as astronaut: searching for biologically useful space in the
chemical universe. Biochem. Pharmacol., 2009, 78: 217-223.
[439] Irwin JJ. Staring off into chemical space. Nat. Chem. Biol., 2009, 5: 536-537.
[440] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V,
Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for
'omics' research on drugs. Nucleic Acids Res., 2011, 39: D1035-D1041.
[441] Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young M P,
Jenkins JL, Glick M, Glen RC, Bender A. From in
silico
target prediction to multi-target
drug design: current databases, methods and applications. J. Proteomics, 2011, 74: 2554-
2574.
[442] Koppen H. Virtual screening - what does it give us? Curr. Opin. Drug Discov. Develop.,
2009, 12: 397-407.
[443] Caldwell GW. Compound optimization in early- and late-phase drug discovery: acceptable
pharmacokinetic properties utilizing combined physicochemical,
in vitro
and
in vivo
screens. Curr. Opin. Drug Discov. Develop., 2000, 3: 30-41.
[444] Raju TNK. The Nobel chronicles. The Lancet, 2000, 356: 346.
[445] DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nat.
Rev. Drug Discov., 2011, 10: 23-27.
[446] Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment
of Indian visceral leishmaniasis. T. Roy. Soc. Trop. Med. H, 2006, 100S: 26-33.
[447] Wermuth CG. Selective optimization of side activities: another way for drug discovery. J.
Med. Chem., 2004, 47: 1303-1314.
[448] Congreve M, Chessari G, Tisi D. Woodhead, A. J. Recent developments in fragment-based
drug discovery. J. Med. Chem., 2008, 51: 3661-3680.
